Relay Therapeutics, Inc.RLAYEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| The Vanguard Group | 8.64% | 10.7M | — | 2024-02-13 |
| BlackRock, Inc. | 7.80% | 9.6M | — | 2024-01-26 |
| Casdin Capital, LLC | 5.99% | 7.4M | ▲ +0.83pp | 2024-02-14 |
| STATE STREET CORPORATION | 3.98% | 75.9K | — | 2024-01-23 |
| T. ROWE PRICE ASSOCIATES, INC. | 3.30% | 5.3M | ▼ -3.70pp | 2024-11-14 |
| FMR LLC | 2.43% | 3.0M | — | 2023-07-10 |
Insider Transactions
Net 90d: −$435.7K · buys $0 / sells $435.7KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-09 | Thomas Catinazzo | Chief Financial Officer | Option exercise | 1.8K | $5.22 | $9.4K |
| 2026-04-09 | Thomas Catinazzo | Chief Financial Officer | Sell (open market) | 1.8K | $15.00 | $27.0K |
| 2026-04-07 | Thomas Catinazzo | Chief Financial Officer | Sell (open market) | 17.7K | $13.01 | $230.5K |
| 2026-03-09 | Thomas Catinazzo | Chief Financial Officer | Sell (open market) | 17.7K | $10.06 | $178.2K |
1–4 of 4